Lexicon Pharmaceuticals (LXRX) Gross Margin (2016 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Gross Margin of 99.49% for Q1 2026, up 187.0% year-over-year from 34.66% in Q1 2025, and up 3.27% quarter-over-quarter from 96.34% in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Gross Margin (2016 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Gross Margin for 10 consecutive years, with 99.49% the latest figure, recorded in Q1 2026.
- In Q1 2026, Gross Margin rose 187.0% year-over-year to 99.49%; the TTM figure through Mar 2026 stood at 99.49% (up 146.0% YoY), while the FY2025 annual figure was 99.45%, up 143.0% from the prior year.
- Gross Margin climbed to 99.49% in Q1 2026 per LXRX's latest filing, from 96.34% in the prior quarter.
- Across five years, Gross Margin topped out at 100.0% in Q2 2022 and bottomed at 89.92% in Q2 2024.
- Historically, Gross Margin has averaged 96.83% across 5 years, with a median of 97.25% in 2023.
- Annual changes were most pronounced in 2024 — Gross Margin tumbled 733 bps — and 2025, when it soared 996 bps.
- Lexicon Pharmaceuticals' Gross Margin stood at 100.0% in 2022, then decreased by 9 bps to 90.86% in 2023, then climbed by 9 bps to 98.69% in 2024, then retreated by 2 bps to 96.34% in 2025, then increased by 3 bps to 99.49% in 2026.
- Business Quant data shows LXRX's Gross Margin at 99.49% in Q1 2026, 96.34% in Q4 2025, and 99.93% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Lexicon Pharmaceuticals | 1.04 Bn | 846.13 Mn | 653,000.00 | 94.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 94.36% |
| Mar 31, 2026 | 99.49% |
| Dec 31, 2025 | 96.34% |
| Sep 30, 2025 | 99.93% |
| Jun 30, 2025 | 99.89% |
| Mar 31, 2025 | 97.62% |
| Dec 31, 2024 | 98.69% |
| Sep 30, 2024 | 95.94% |
| Jun 30, 2024 | 89.92% |
| Mar 31, 2024 | 97.16% |
| Dec 31, 2023 | 90.86% |
| Sep 30, 2023 | 95.68% |
| Jun 30, 2023 | 97.25% |
| Jun 30, 2022 | 100.00% |
| Dec 31, 2020 | 100.00% |
| Jun 30, 2020 | -2,812.00% |
| Mar 31, 2020 | 92.90% |
| Dec 31, 2019 | 91.13% |
| Sep 30, 2019 | 99.80% |
| Jun 30, 2019 | -54.30% |